An international survey, led by the University of Queensland’s Dr Richard Bade and conducted during a week over the New Year periods of 2022-23 and 2023-24 found 2 nitazene variants – protonitazene and etonitazepyne – at 4 treatment plants in the US and 1 in Australia.


